Trial Profile

Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zanidatamab (Primary) ; Capecitabine; Paclitaxel; Tucatinib; Vinorelbine
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Gynaecological cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Parotid cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Zymeworks

27 Nov 2024 Status changed from active, no longer recruiting to completed.
15 Aug 2024 Planned End Date changed from 1 Jul 2024 to 31 Oct 2024.
15 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 31 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com